Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3537982 in Participants With Renal Impairment
NCT07137689Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration, Area Under the Concentration Verses Time Curve from Time Zero to Infinity and 1 more. Started Aug 2025; status: completed.
02
Drugs
olomorasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07137689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137689.